Home » Stocks » VACC

Vaccitech plc (VACC)

Stock Price: $16.77 USD 1.02 (6.48%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 571.26M
Revenue (ttm) 4.82M
Net Income (ttm) -17.71M
Shares Out 34.06M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $16.77
Previous Close $15.75
Change ($) 1.02
Change (%) 6.48%
Day's Open 16.19
Day's Range 15.76 - 17.87
Day's Volume 181,873
52-Week Range 12.25 - 17.87

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

OXFORD, United Kingdom, May 04, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...

1 week ago - GlobeNewsWire

Here's how VACC stock has performed thus far following the company's highly anticipated IPO in the market today. The post VACC Stock IPO: 7 Things to Know as Vaccitech Starts Trading Today appeared firs...

2 weeks ago - InvestorPlace

OXFORD, United Kingdom, April 29, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (“Vaccitech”) (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immuno...

2 weeks ago - GlobeNewsWire

Biotech startup Vaccitech Plc, which owns the technology behind the COVID-19 vaccine developed by Oxford University and AstraZeneca Plc, filed for a U.S. initial public offering on Friday.

1 month ago - Reuters

Vaccitech plc has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

Vaccitech's decision to float in the US is a blow to the UK but its success reveals some important and reassuring developments.

1 month ago - Sky News

Sarah Gilbert, Adrian Hill and Oxford University to get windfalls when Covid vaccine firm Vaccitech goes public

1 month ago - The Guardian

About VACC

Vaccitech is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. We use our proprietary platform to develop product candidates that stimulate powerful, targeted immune responses against pathogens and tumor cells. We design our product candidates to stimulate immune responses that are robust, highly specific, and are differentiated by the magnitude of the T cell populations induced, which exhibit critical f... [Read more...]

Industry
Biotechnology
IPO Date
Apr 30, 2021
CEO
William Enright
Employees
48
Stock Exchange
NASDAQ
Ticker Symbol
VACC
Full Company Profile

Financial Performance

In 2020, Vaccitech's revenue was $4.82 million, a decrease of -29.58% compared to the previous year's $6.85 million. Losses were -$17.71 million, -14.59% less than in 2019.

Financial Statements